0 rating

Clinical Dermatology

McKay KM, Sambrano BL, Fox PS et al.

The University of Alabama at Birmingham, Birmingham, AL, USA.

 Br J Dermatol 2013;169:549–54.

Jürgen Schauber’s review: Basal cell carcinoma (BCC) is the most common malignancy in the Caucasian population, and the incidence of BCC is rising dramatically. Hence, BCCs are prominent drivers of healthcare costs, and cause significant morbidity. Several topical, noninvasive treatments have been introduced for superficial BCC (sBCC), with topical imiquimod being one such effective alternative to surgical excision. However, these topical therapies only cure superficial tumors, and there are currently no uniform histological definitions of sBCC. Recurring tumors or deeply penetrating BCCs cannot be treated by topical agents but must be excised surgically. Therefore, a definition of BCCs based on tumor thickness may help guide treatment decisions.

Return to top

RELATED ARTICLES

Cellular Phone Dermatitis
Mariko Seishima
CML Dermatology
Atopic Dermatitis: A Review and Evaluation of Treatment with Omalizumab
Lananh T Do, Asif Rafi, and Roger M Katz
CML Dermatology
Current Literature on Basal-Like Breast Cancers
Nicholas Turner
CML Breast Cancer
Dietary Pseudoallergens and Chronic Urticaria
Emma K Wedgeworth, MA, MRCP and Clive EH Grattan, MA, MD, FRCP
CML Dermatology
Current and Future Therapies for Treating Atopic Dermatitis in Pediatric Patients
Mary K Tholman1, Laura J Lester1, and Adelaide A Hebert, MD1,2
Advances in Psoriasis and Inflammatory Skin Diseases

LATEST ARTICLES